ArticleAlcoholism treatment quarterly2026
10-Butyl Ether Minocycline (BEM) Reduced Ethanol Consumption in Binge Drinking Mice.
Article in Alcoholism treatment quarterly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Alcohol use disorder (AUD) is a complex brain disease with high morbidity, mortality, and limited treatment options, causing significant societal burden. Minocycline, well known for its anti-inflammatory and immunomodulatory properties, could potentially treat AUD but its antimicrobial activity would be inessential, and even a liability, for long-term treatment in AUD patients. 10-Butyl Ether Minocycline (BEM) was synthesized to retain minocycline's off-target actions and eliminate antimicrobial properties. We hypothesized that BEM would reduce high ethanol consumption in common murine models of binge drinking without affecting ethanol elimination. The Drinking-In-the-Dark (DID) paradigm was used to assess BEM's efficacy in reducing binge-like ethanol consumption. BEM dose-responsively reduced ethanol consumption in both female and male mice. Ethanol elimination following administration of both BEM and ethanol was evaluated using gas chromatography. BEM had no effect on ethanol metabolism in either sex, suggesting that its mechanism is independent and, thus, should not exacerbate ethanol-related toxicity when the two are taken together. Previous findings showed BEM effectively reduced chronic ethanol consumption. Future studies are underway to evaluate BEM's potential as an AUD treatment, which so far have shown BEM to be safer than minocycline and inexpensive to produce.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.